去甲基化药物在骨髓增生异常综合征患者异基因造血干细胞移植中应用的研究进展

Research progress of hypomethylating agents in myelodysplastic syndrome patients with allogeneic hematopoietic stem cell transplantation

去甲基化药物（HMA）在骨髓增生异常综合征（MDS）患者中具有良好的抗肿瘤作用.目前,MDS患者于接受异基因造血干细胞移植（allo-HSCT）前,应用HMA作为桥接治疗是减少该病患者肿瘤负荷的重要治疗方法之一.同时,研究显示,MDS患者于接受allo-H SCT后应用HMA,对于预防及延缓疾病复发具有一定作用.笔者拟就MDS患者在接受allo-HSCT前、后应用HMA的研究进展进行综述如下.

Hypomethylating agents （HMA） have shown good antitumor effects in myelodysplastic syndrome （MDS） patients.At present,before allogeneic hematopoietic stem cell transplantation （alloHSCT）,the application of HMA is an important bridge treatment method to reduce the tumor load of MDS patients.At the same time,some studies show that the application of HMA after allo-HSCT plays a certain role in preventing or delaying the recurrence of disease.The author will review the application of HMA in MDS patients with allo-HSCT from the aspect of before and after allo-HSCT.